Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Batch-dependent safety signal: Nationwide analysis of suspected adverse events following COVID-19 vaccination in Germany.

The International journal of risk & safety in medicine·2026
Same author

High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study.

International journal of cardiology. Heart & vasculature·2025
Same author

Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.

European heart journal·2025
Same author

Safety of BNT162b2 mRNA COVID-19 Vaccine Batches: A Nationwide Cohort Study.

Pharmacoepidemiology and drug safety·2025
Same author

Antibodies to Periodontal Bacteria Are Associated with Systemic Lupus Erythematosus and Autoantibody Positivity.

International journal of molecular sciences·2025
Same author

Descriptive Analysis of Periodontitis Case Detection and Selected Comorbidities in Danish Private Dental Practices.

Journal of clinical periodontology·2025

Related Experiment Video

Updated: Jun 26, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

[Peripartum cardiomyopathy].

Ditte-Marie Bretler1, Casper Haslund Jørgensen, Jonas Bjerring Olesen

  • 1Gentofte Hospital, Kardiologisk Afdeling P, DK-2900 Hellerup. dimabr01@geh.regionh.dk

Ugeskrift for Laeger
|January 9, 2009
PubMed
Summary

Peripartum cardiomyopathy, a rare heart failure in women, may be caused by prolactin. Bromocriptine treatment shows promise in ameliorating this condition by blocking prolactin release.

Area of Science:

  • Cardiology
  • Endocrinology
  • Reproductive Medicine

Context:

  • Peripartum cardiomyopathy (PPCM) is a rare but serious condition.
  • It presents as heart failure in previously healthy women during late pregnancy or early postpartum.
  • PPCM has significant morbidity and mortality rates.

Purpose:

  • To review the literature on peripartum cardiomyopathy.
  • To highlight recent findings on the molecular mechanisms of PPCM.
  • To discuss potential therapeutic interventions for PPCM.

Summary:

  • Recent data suggest an antiangiogenic prolactin cleavage product is involved in PPCM pathogenesis.
  • Blocking prolactin release with bromocriptine may improve PPCM outcomes.
  • This review emphasizes the role of prolactin in PPCM and bromocriptine's therapeutic potential.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

An Intact Pericardium Ischemic Rodent Model
07:15

An Intact Pericardium Ischemic Rodent Model

Published on: September 2, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

An Intact Pericardium Ischemic Rodent Model
07:15

An Intact Pericardium Ischemic Rodent Model

Published on: September 2, 2021

Impact:

  • Provides insights into the molecular basis of PPCM.
  • Suggests a novel therapeutic strategy targeting prolactin.
  • Offers hope for improved management of peripartum heart failure.